Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe … (NCT03915366) | Clinical Trial Compass
CompletedPhase 2/3
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Côte d’Ivoire, France, Italy563 participantsStarted 2020-03-01
Plain-language summary
This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.
Who can participate
Age range28 Days – 365 Days
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 28 days to 365 days of age
✓. Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60 days of age ≥60 breaths per minute and for infants 61 to 365 days of age, ≥50 breaths per minute.
✓. Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1 or more criteria)
✓. Chest indrawing with HIV infection
✓. No improvement with oral treatment.
✓. One or more danger signs according to WHO 5,44,45
✓. HIV-confirmed infection (with at least one molecular method: DNA polymerase chain reaction (PCR) or RNA PCR/viral load).
✓. Informed consent obtained
Exclusion criteria
✕. Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB-T prescribed by a physician, at the moment of randomization
✕. Known bacteriologically confirmed TB case (at least one biological specimen positive by culture or Xpert MTB/RIF) at the moment of randomization
✕. Patient previously treated for TB or currently on treatment for TB
✕. Documented evidence of close TB exposure (household contact of a patient with documented TB during the lifetime of the child, or currently receiving TB-T)
✕. Pure wheezers defined as a clear clinical improvement after a bronchodilator test (give a challenge of rapid-acting inhaled bronchodilator for up to three times 15-20 minutes apart. Count the breaths and look for chest indrawing again, and then re-classify)
✕. Active malignancies
✕. Systemic immunosuppressive medications. Steroids will be considered to be immunosuppressing only if \>2 mg/kg of prednisone or equivalent during \>15 days
✕. Evidence of condition other than HIV and pneumonia which precludes, to the judgment of the clinical researcher, enrollment in this trial due to risk for the patient. In case of doubt, the Trial Management Team will be contacted to assess eligibility